InventisBio (SH:688382) Orient Securities·2025-05-31 14:26Investment Rating - The report maintains a "Buy" rating for the company with a target price of 28.24 CNY, reflecting a reasonable market value of 163.33 billion CNY [2][6]. Core Insights - The company has shown a narrowing of losses, with a reported revenue of 1.69 billion CNY in 2024, a decrease of 9.0% year-on-year, and a net loss of 240 million CNY, which is a reduction of 15.4% compared to the previous year [9]. - The approval of the drug Gexosrayse for commercialization is expected to enhance revenue streams, with 2025 being the first full year of commercialization for this product [9]. - The clinical pipeline is progressing well, with positive data from the TYK2 inhibitor trials, indicating strong potential for future growth [9]. Financial Forecasts - Revenue projections for 2025-2027 have been adjusted downwards, with expected net profits of -346 million CNY, -377 million CNY, and -290 million CNY respectively [2]. - The company is expected to achieve a significant revenue increase in 2026 and 2027, with growth rates of 129.3% and 62.6% respectively [4]. - The gross margin is projected to remain high, around 100% in 2025, while the net margin is expected to improve significantly by 2027 [4]. Financial Metrics - The company reported a net profit margin of -153.1% in 2023, which is expected to improve to -55.1% by 2027 [4]. - The earnings per share (EPS) is projected to be -0.60 CNY in 2025, improving to -0.50 CNY by 2027 [4]. - The price-to-earnings (P/E) ratio is forecasted to be -40.6 in 2025, indicating the company's current valuation relative to its earnings [4].